Alternatives to Quinn

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Owkin's K Pro is an autonomous AI scientist agent that informs biopharma R&D, clinical trial and portfolio decisions.

Physics-based simulation plus AI for molecular discovery across drug and materials design.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

AI agents that assemble clinical evidence into quantitative models for trial design, dose selection and go/no-go decisions.

Cellbyte is an AI workspace for pharmaceutical Pricing & Market Access teams, turning HTA and pricing research from weeks into minutes.

Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease through partnership-led discovery.

Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.

Oncology real-world evidence platform turning patient data into AI-assisted cancer research insights.

Cloud ELN, LIMS, and AI platform that unifies biotech R&D data for discovery teams.

FDA-cleared AI for cancer pathology: prostate, breast, GI and pan-cancer detection on H&E slides, plus Virchow foundation models for research.

Cloud-based medical imaging platform that turns MRI, CT, and PET scans into regulatory-cleared quantitative imaging biomarkers.

PathAI is an enterprise digital pathology platform for diagnostic accuracy and biopharma drug development.

Dotmatics Luma: agentic AI that plans, executes, and completes R&D data analysis, report generation and platform configuration for multimodal scientific

AI platform that designs and predicts molecular constructs for gene and RNA therapies before they reach the lab

An AI co-scientist that chains 150+ biological tools to run multi-omics, clinical genomics, and drug discovery analysis from plain-language prompts.

NExTNet pairs evidence-backed Copilot answers with Explorer's connected knowledge maps for life sciences research.

A research-stage AI platform for discovering neurotherapeutics that act on neural circuits across multiple disorders.

Lamin is an open data platform and open-source LaminDB library for lineage tracking, multimodal lakehouse storage, and FAIR dataset governance in computational

Open-source benchmark scoring AI reasoning on therapeutic decision-making, with a 2026 software-engineering edition.

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

PicnicAI turns patient health records into clinical research data and real-world evidence.

AI models that design peptide-LNP targeting systems to deliver genetic medicines to chosen cell types

BioStack Platforms supplies structured clinical datasets and RL environments for healthcare AI teams.

Clinical-stage AI drug discovery company running a wet-and-dry lab-in-the-loop engine with 2M weekly experiments and a 50+ PB phenomics dataset

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Silico is Goodfire's interpretability agent for understanding, debugging, and controlling the internals of your AI models

All-in-human AI foundation models that predict brain activity and therapy response for CNS drug programs

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.